Skip to main
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 0%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Personalis is poised for strong growth with their expanding sales force, positive financials, and partnerships with leading companies. Their recent Medicare coverage for their NeXT Personal MRD test and potential partnerships with Tempus and Moderna further solidify their position in the market. However, competition and regulatory challenges may pose risks for the company's future success.

Bears say

Personalis is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The negative outlook is driven by concerns over the company's high dependence on its biopharma business and the potential impact of volatility in ordering patterns and funding from the U.S. Department of Veterinary Affairs. Additionally, the company's recent cross-licensing deal with Myriad Genetics for its intellectual property could indicate challenges in competing in the clinical MRD testing market. The company's recent publication of results from its early stage breast cancer study is promising, but it remains to be seen if it will translate into significant revenue growth.

Personalis Inc (PSNL) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 0% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Personalis Inc (PSNL) has a Strong Buy consensus rating as of May 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.